Literature DB >> 11328372

Perpetuation of immunological memory: a relay hypothesis.

R Nayak1, S Mitra-Kaushik, M S Shaila.   

Abstract

A mechanism is proposed which explains the perpetuation of B-cell immunological memory indefinitely without requiring the presence of long-living memory cells or persisting antigen. The salient feature of this model is that immunological memory can be perpetuated indefinitely through the mutual interaction of idiotypic and anti-idiotypic B cells. These cells mutually stimulate and clonally expand with either specific or bystander T-cell help. Because B cells can present antigen, they present 'apparently foreign' idiopeptides to T cells. The idiopeptides of de novo synthesized antibody is presented to CD8+ T cells that recognize the idiopeptide-presenting cell as targets and regulate their population. The recycling of immunoglobulins from surface to endosomal compartment of B cells leads to the presentation of idiopeptides by major histocompatibility complex (MHC) class II to CD4+ T cells. Even if the majority of the clonally expanded cells die because of lack of stimulation, cytotoxic T lymphocyte (CTL) lysis or for other reasons, the surviving cells will be able to carry forward the memory. This mechanism also provides a means for affinity maturation through idiotypic selection of somatically mutated high affinity cells or those from the naïve pool. We have termed these two types of complementary B cells as Burnet B cells: those which recognize the antigen or antigen mimic, and Jerne B cells, which can recognize the idiotypes of antibody and carry antigen mimics. The proposed hypothesis can explain differential duration of memory for different antigens, the shelf space paradox, affinity maturation, repertoire shift, etc.

Mesh:

Year:  2001        PMID: 11328372      PMCID: PMC1783194          DOI: 10.1046/j.1365-2567.2001.01205.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

Review 1.  Memory in the B-cell compartment: antibody affinity maturation.

Authors:  M S Neuberger; M R Ehrenstein; C Rada; J Sale; F D Batista; G Williams; C Milstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

2.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

Authors:  U Schubert; L C Antón; J Gibbs; C C Norbury; J W Yewdell; J R Bennink
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

3.  Memory B-cell persistence is independent of persisting immunizing antigen.

Authors:  M Maruyama; K P Lam; K Rajewsky
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

4.  Molecular mimicry of human tumor antigen by heavy chain CDR3 sequence of the anti-idiotypic antibody.

Authors:  D Luo; W Qi; J Ma; Y J Wang; D Wishart
Journal:  J Biochem       Date:  2000-09       Impact factor: 3.387

5.  Class II-independent generation of CD4 memory T cells from effectors.

Authors:  S L Swain; H Hu; G Huston
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

6.  Persistence of memory CD8 T cells in MHC class I-deficient mice.

Authors:  K Murali-Krishna; L L Lau; S Sambhara; F Lemonnier; J Altman; R Ahmed
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

7.  The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.

Authors:  C A Janeway; J Ron; M E Katz
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

8.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

9.  The major substrates for TAP in vivo are derived from newly synthesized proteins.

Authors:  E A Reits; J C Vos; M Grommé; J Neefjes
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

10.  Anti-idiotype antibody-dependent cell-mediated cytotoxicity (ADCC) against idiotype-bearing cells.

Authors:  J Caraux; W O Weigle
Journal:  Cell Immunol       Date:  1983-05       Impact factor: 4.868

View more
  7 in total

Review 1.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

2.  Maintenance of antigen-specific immunological memory through variable regions of heavy and light chains of anti-idiotypic antibody.

Authors:  J Vani; R Nayak; M S Shaila
Journal:  Immunology       Date:  2007-01-11       Impact factor: 7.397

3.  ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset.

Authors:  Fariba Vaziri-Sani; Shilpa Oak; Jared Radtke; Ke Lernmark; Kristian Lynch; Carl-D Agardh; Corrado M Cilio; Asa L Lethagen; Eva Ortqvist; Mona Landin-Olsson; Carina Törn; Christiane S Hampe
Journal:  Autoimmunity       Date:  2010-03-19       Impact factor: 2.815

Review 4.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

5.  The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes.

Authors:  Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-26       Impact factor: 11.205

Review 6.  Immunogenic properties of immunoglobulin superfamily members within complex biological networks.

Authors:  Josué Odales; Jesus Guzman Valle; Fernando Martínez-Cortés; Karen Manoutcharian
Journal:  Cell Immunol       Date:  2020-10-11       Impact factor: 4.868

7.  Structural basis for the function of anti-idiotypic antibody in immune memory.

Authors:  J Vani; Jhinuk Chatterjee; M S Shaila; R Nayak; Nagasuma R Chandra
Journal:  Mol Immunol       Date:  2009-01-20       Impact factor: 4.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.